

# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ivermectin / Pyrantel Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

20 Spartan Road

1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

# 1.4 Emergency telephone number

+1-908-423-6000

# **SECTION 2: Hazards identification**

# 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Short-term (acute) aquatic hazard, Cate-

gory 1

H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Cat-

egory 1

H410: Very toxic to aquatic life with long lasting

effects.

#### 2.2 Label elements

# Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Warning

Hazard statements : H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

P273 Avoid release to the environment.

Response:

P391 Collect spillage.

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment:  $8,6\,\%$ 

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number 22204-24-6	Classification	Concentration (% w/w)
4,4'-methylenebis[3-hydroxy-2- naphthoic] acid, compound with (E)- 1,4,5,6-tetrahydro-1-methyl-2-[2-(2- thienyl)vinyl]pyrimidine (1:1)	244-837-1		>= 1 - < 10
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ————————————————————————————————————	>= 0,0025 - < 0,025

For explanation of abbreviations see section 16.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

#### **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

# 4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

#### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

## 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

Sulphur oxides Metal oxides

Chlorine compounds

5.3 Advice for firefighters

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

## 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Us Advice on safe handling : Do

Use only with adequate ventilation.

Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

# 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

#### **SECTION 8: Exposure controls/personal protection**

# 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
4,4'- methylenebis[3- hydroxy-2- naphthoic] acid, compound with (E)-1,4,5,6- tetrahydro-1- methyl-2-[2-(2- thienyl)vinyl]pyrimi dine (1:1)	22204-24-6	TWA	250 μg/m3 (OEB 2)	Internal
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 μg/100 cm2	Internal



# **Ivermectin / Pyrantel Formulation**

VersionRevision Date:SDS Number:Date of last issue: 30.09.20235.006.04.202452653-00031Date of first issue: 02.02.2015

# Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
D-Glucono-1,5- lactone	Workers	Inhalation	Long-term systemic effects	59 mg/m3
	Workers	Skin contact	Long-term systemic effects	11,9 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	14,6 mg/m3
	Consumers	Skin contact	Long-term systemic effects	5,9 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5,9 mg/kg bw/day
Sodium chloride	Workers	Inhalation	Long-term systemic effects	2068,62 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	2068,62 mg/m3
	Workers	Skin contact	Long-term systemic effects	295,52 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	295,52 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	443,28 mg/m3
	Consumers	Inhalation	Acute systemic effects	443,28 mg/m3
	Consumers	Skin contact	Long-term systemic effects	126,65 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef- fects	126,65 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	126,65 mg/kg bw/day
	Consumers	Ingestion	Acute systemic ef- fects	126,65 mg/kg bw/day

# Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

	, ,	` '
Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry weight (d.w.)



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

	Soil	50 mg/kg dry weight (d.w.)
D-Glucono-1,5-lactone	Fresh water	0,1 mg/l
	Marine water	0,01 mg/l
	Intermittent use/release	1 mg/l
	Sewage treatment plant	6,498 mg/l
	Fresh water sediment	0,36 mg/kg dry weight (d.w.)
	Marine sediment	0,36 mg/kg dry weight (d.w.)
	Soil	0,014 mg/kg dry weight (d.w.)
Sodium chloride	Fresh water	5 mg/l
	Sewage treatment plant	500 mg/l
	Soil	4,86 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

# **SECTION 9: Physical and chemical properties**

# 9.1 Information on basic physical and chemical properties

Appearance : powder Colour : brown



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

Odour : No data available
Odour Threshold : No data available

pH : 4 - 6 (20 °C)

(as aqueous solution)

Melting point/freezing point : No data available

Initial boiling point and boiling

range

: No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

No data available

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : Not applicable

Molecular weight : No data available

Particle size : No data available



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

# **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

# 11.1 Information on toxicological effects

Information on likely routes of : Ir

exposure

Inhalation Skin contact

Ingestion

Eye contact

#### **Acute toxicity**

Not classified based on available information.

#### **Components:**

# 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity : LD50 (Rat): > 24.000 mg/kg

LD50 (Mouse): > 24.000 mg/kg

LD50 (Dog): 2.000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 52653-00031 Date of first issue: 02.02.2015

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

### **Components:**

#### Ivermectin:

Species : Rabbit

Result : No skin irritation

# Serious eye damage/eye irritation

Not classified based on available information.

## **Components:**

# Ivermectin:

Species : Rabbit

Result : Mild eye irritation

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

#### Ivermectin:



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1,5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2,0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

#### Reproductive toxicity

Not classified based on available information.

#### Components:

# 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal develop- : Test Type: Embryo-foetal development

ment Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 3.000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1.000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

#### Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

Fertility: NOAEL: 0,6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0,2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0,4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

#### STOT - single exposure

Not classified based on available information.

#### Components:

#### Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

#### STOT - repeated exposure

Not classified based on available information.

# **Components:**

#### Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

#### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Species : Dog NOAEL : 10 mg/kg



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

LOAEL : 30 mg/kg
Application Route : Ingestion
Exposure time : 3 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 19 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

#### Ivermectin:

Species: DogNOAEL: 0,5 mg/kgLOAEL: 1 mg/kgApplication Route: OralExposure time: 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1,2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 0,4 mg/kg

LOAEL : 0,8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

## **Aspiration toxicity**

Not classified based on available information.

# Experience with human exposure

#### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea,

Headache, Dizziness, Fever

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

## **SECTION 12: Ecological information**

## 12.1 Toxicity

## **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

#### **Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

city)

10.000

M-Factor (Chronic aquatic

10.000

toxicity)

## 12.2 Persistence and degradability

#### **Components:**

Ivermectin:

Biodegradability : Result: Not readily biodegradable.



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

Biodegradation: 50 % Exposure time: 240 d

#### 12.3 Bioaccumulative potential

#### **Components:**

#### Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

: log Pow: 3,22

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Other adverse effects

#### **Product:**

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## **SECTION 14: Transport information**

#### 14.1 UN number

**ADN** : UN 3077 **ADR** : UN 3077



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

 RID
 : UN 3077

 IMDG
 : UN 3077

 IATA
 : UN 3077

14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

( - - - - - )

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

**IATA** : Environmentally hazardous substance, solid, n.o.s.

(Ivermectin)

14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**ADR** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG** 



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

**ADN** 

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

**SECTION 15: Regulatory information** 

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 52653-00031
 Date of first issue: 02.02.2015

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H300 : Fatal if swallowed.

H311 : Toxic in contact with skin.

H370 : Causes damage to organs if swallowed.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization: IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet;



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 52653-00031 Date of first issue: 02.02.2015

SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 1 H410 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN